ENCell, a Korean company specializing in cell and gene therapy CDMO services, said Monday that it will attend the 43rd J.P. Morgan Healthcare Conference in San Francisco, California, from next Monday to Jan. 16, marking the start of its global partnering efforts.

Since its Kosdaq listing in August 2023, ENCell has been expanding its network with global partners. 

The company plans to use its participation in the conference to actively promote its services and focus on partnering opportunities with key companies and investors. ENCell aims to highlight its expertise in cell and gene therapy CDMO services, its GMP production capabilities meeting global standards, and its ongoing efforts to license out its new drug pipeline, including EN001.

EN001, the leading product in ENCell's pipeline, is a next-generation allogeneic mesenchymal stem cell therapy developed with the company's proprietary technology.

In June 2023, ENCell completed a phase 1 clinical trial involving nine patients with Charcot-Marie-Tooth disease (CMT) type 1A. The company recently initiated a phase 1b trial to evaluate the safety and efficacy of repeated high-dose EN001 treatments in CMT type 1A patients.

ENCell said it has already scheduled partnering meetings with global companies, though the identities of these companies have not been disclosed.